BNTX:NASDAQ
BioNTech SE - ADR
$95.83
arrow_downward
-0.89%(-0.86) 1D
$96.59
arrow_upward
+0.79% (+0.76)todayPre-market
Closed: Sep 16, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$97.24
High
$97.32
Low
$95.32
Mkt. cap
24.07B
Avg. vol.
1.54M
Volume
1.66K
52-wk high
$124.00
52-wk low
$79.52
EPS
-$7.74
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$97.24
High
$97.32
Low
$95.32
Mkt. cap
24.07B
Avg. vol.
1.54M
Volume
1.66K
52-wk high
$124.00
52-wk low
$79.52
EPS
-$7.74
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Investing.com
·
19 hours ago
UBS reiterates Buy on BioNTech stock after lung cancer data
Yahoo Finance
·
1 day ago
BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
Yahoo Finance
·
2 days ago
Why Is BioNTech Stock Gaining Monday?
Stock Titan
·
3 days ago
BioNTech’s experimental treatment extended survival to 18.5 months, versus 10
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR